Finance

Lists
Why is NUVB down 3,67%?
Dive Deeper
NUVB:NYSE
Nuvation Bio Inc
USD 4,72
-3,67%
(-0,18) 1D
USD 4,74
+0,42% (+0,020)
After hours
Closed: 13 Okt., 16:00:05 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NUVB...
Open
USD 4,86
High
USD 4,92
Low
USD 4,71
Mkt. cap
1,66 mjd
Avg. vol.
5,30 m
Volume
7,61 m
52-wk high
USD 9,75
52-wk low
USD 3,36
EPS
-USD 0,44
Beta
1,61
Shares outstanding
351,12 m
No. of employees
305
Open
USD 4,86
High
USD 4,92
Low
USD 4,71
Mkt. cap
1,66 mjd
Avg. vol.
5,30 m
Volume
7,61 m
52-wk high
USD 9,75
52-wk low
USD 3,36
EPS
-USD 0,44
Beta
1,61
Shares outstanding
351,12 m
No. of employees
305
News stories
From web sources and news partners
About Nuvation Bio Inc
CEODavid Hung
Employees305
Founded2018
Headquarters-
SectorPharmaceutical industry
Websitenuvationbio.com
Analyst ratings
Based on 9 analysts giving stock ratings to NUVB in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for NUVB in the last 3 months.
Highest
Current USD 4,72
USD 21,00 (+344,92%)
Average
USD 14,57 (+208,69%)
Lowest
USD 11,00 (+133,05%)
Analyst
Recommendation
Action
Price target
Projected
Date
Leonid Timashev
RBC Capital
Buy
Maintained
USD 20,00
+323,7%
10/08/2026
Geoff Meacham
Citi
Buy
Initiated
USD 12,00
+154,2%
10/01/2026
Priyanka Grover
J.P. Morgan
Buy
Maintained
-
-
09/15/2026
David Nierengarten
Wedbush
Buy
Maintained
USD 11,00
+133,1%
09/15/2026
Gregory Renza
Truist Financial
Buy
Maintained
-
-
09/15/2026
Li Watsek
Cantor Fitzgerald
Buy
Initiated
USD 12,00
+154,2%
08/21/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
USD 14,00
+196,6%
08/07/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
USD 21,00
+344,9%
08/07/2026
Boris Peaker
JonesTrading
Buy
Reiterated
USD 12,00
+154,2%
08/06/2026
Yaron Werber
TD Cowen
Buy
Reiterated
-
-
06/01/2026
Soumit Roy
JonesTrading
Buy
Maintained
USD 12,00
+154,2%
04/06/2026
Michael Yee
UBS
Hold
Maintained
USD 7,00
+48,3%
03/03/2026
Last report
06 Aug. 2026
Fiscal period
Q2 2026
-USD 0,15 / -USD 0,12
-25,15%miss
Revenue / Est. (USD)
31,69 m / 28,70 m
+10,42%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
13,12 m
41,86 m
83,23 m
31,69 m
Cost of goods sold
3,35 m
1,28 m
5,99 m
9,47 m
Cost of revenue
3,35 m
1,28 m
5,99 m
9,47 m
Research and development expenses
28,85 m
34,30 m
35,05 m
30,66 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
37,36 m
40,33 m
38,31 m
42,59 m
Operating expense
66,20 m
74,62 m
73,36 m
73,25 m
Total operating expenses
69,55 m
75,90 m
79,35 m
82,72 m
Operating income
-56,43 m
-34,04 m
3,88 m
-51,04 m
Other non operating income
1,14 m
-1,18 m
3,11 m
-179,00 k
EBT including unusual items
-55,79 m
-36,59 m
5,40 m
-62,84 m
EBT excluding unusual items
-55,80 m
-36,59 m
5,39 m
-53,38 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-55,79 m
-36,59 m
5,40 m
-62,84 m
Net profit margin
-425,24%
-87,40%
6,48%
-198,31%
Earnings per share
-0,14
-0,09
0,04
-0,15
Interest and investment income
6,03 m
5,30 m
5,11 m
4,60 m
Interest expense
-6,53 m
-6,67 m
-6,71 m
-6,76 m
Net interest expenses
-501,00 k
-1,38 m
-1,60 m
-2,16 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-55,90 m
-33,50 m
4,42 m
-50,50 m
Gain or loss from assets sale
-4,00 k
3,00 k
-
-1,00 k
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme